Title |
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
|
---|---|
Published in |
Radiation Oncology, October 2008
|
DOI | 10.1186/1748-717x-3-36 |
Pubmed ID | |
Authors |
Michael T Milano, Louis S Constine, Paul Okunieff |
Abstract |
Stereotactic body radiation (SBRT) is an emerging tool in radiation oncology in which the targeting accuracy is improved via the detection and processing of a three-dimensional coordinate system that is aligned to the target. With improved targeting accuracy, SBRT allows for the minimization of normal tissue volume exposed to high radiation dose as well as the escalation of fractional dose delivery. The goal of SBRT is to minimize toxicity while maximizing tumor control. This review will discuss the basic principles of SBRT, the radiobiology of hypofractionated radiation and the outcome from published clinical trials of SBRT, with a focus on late toxicity after SBRT. While clinical data has shown SBRT to be safe in most circumstances, more data is needed to refine the ideal dose-volume metrics. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 2 | 2% |
United Kingdom | 1 | <1% |
Belgium | 1 | <1% |
Netherlands | 1 | <1% |
Spain | 1 | <1% |
Denmark | 1 | <1% |
United States | 1 | <1% |
Philippines | 1 | <1% |
Unknown | 99 | 92% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 25 | 23% |
Other | 18 | 17% |
Student > Ph. D. Student | 17 | 16% |
Professor > Associate Professor | 10 | 9% |
Professor | 6 | 6% |
Other | 25 | 23% |
Unknown | 7 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 63 | 58% |
Physics and Astronomy | 13 | 12% |
Biochemistry, Genetics and Molecular Biology | 4 | 4% |
Agricultural and Biological Sciences | 4 | 4% |
Engineering | 3 | 3% |
Other | 9 | 8% |
Unknown | 12 | 11% |